title: PTEN and MDM2 expression in the prediction of postmolar gestational trophoblastic neoplasia.
abstract: OBJECTIVE
  To investigate the role of PTEN and MDM2 expression in hydatidiform mole in the prediction of postmolar gestational trophoblastic neoplasia (GTN).
  
  
  METHODS
  A total of 145 cases of hydatidiform mole were diagnosed at the King Chulalongkorn Memorial Hospital from 1999 to 2010. Patients were classified into 2 groups: spontaneous remission and patients with postmolar GTN. Clinicopathologic features and immunohistochemical staining by PTEN and MDM2 were reviewed. The results were analyzed in correlation to the clinical characteristics and outcomes.
  
  
  RESULTS
  Of 145 recruited cases, 128 (88.3%) cases were complete hydatidiform mole (CHM) and 17 (11.7%) cases were partial hydatidiform mole (PHM). Postmolar GTN was clinically diagnosed in 42 cases (28.9%). The incidences of postmolar GTN following CHM and PHM were 29.7% and 23.5%, respectively. Mean age of the postmolar GTN group was significantly older than that of the remission group (31.2 vs. 27.8, p = 0.04). There was no significant difference of pathologic features between cases with remission and postmolar GTN. Immunoreactivity of PTEN and MDM2 were similarly present in trophoblastic cells of both CHM and PHM groups without significantly different patterns.
  
  
  CONCLUSIONS
  Immunohistochemical expression of PTEN and MDM2 in hydatidiform mole cannot predict molar malignant transformation.
authors: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. drruang9@yahoo.com
authors: Ruangsak
authors: R
authors: Lertkhachonsuk
authors: Patou
authors: P
authors: Tantbirojn
authors: Krissada
authors: K
authors: Paiwattananupant
mesh_terms: D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000097:blood; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000175:diagnosis / Q000378:metabolism*; D006801:Humans; D006828:Hydatidiform Mole / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy; D007044:Hysterectomy; D007150:Immunohistochemistry; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D011247:Pregnancy; D051736:Proto-Oncogene Proteins c-mdm2 / Q000378:metabolism*; D012075:Remission, Spontaneous; D014594:Uterine Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D006063:Chorionic Gonadotropin; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human